对外授权及产品商业化驱动营收大幅增长

东方财富
Nov 05, 2025

智翔金泰(688443)核心观点对外授权及产品商业化驱动营收大幅增长。2025年前三季度,公司实现营收2.08亿元,较上年同期大幅增长,主要系公司在报告期内确认GR1803注射液授权许可及商业化协议的合同履约义务所对应的授权许可收入,以及公司首款商业化产品赛立奇单抗注射液(商品名:金立希)销售收入较上年同期有所增长所致;实现归母净利润-3.33亿元,亏损较上年同期收窄,主要系公司对外授权收入及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10